These warnings are listed in the drugs prescribing information
2.3 Appetite Suppression and Central Regulation GLP-1 receptor activation within the hypothalamus influences: Pro-opiomelanocortin (POMC) neurons Appetite-regulating neurocircuitry Food reward signalling Randomised controlled trials demonstrate significant reductions in caloric intake in patients treated with semaglutide or tirzepatide. Reduced energy intake is the principal driver of weight loss
Binge eating, not followed by recurrent use of inappropriate compensatory behaviors, often results in weight gain, and for this reason, some individuals make several attempts to lose weight
Practical Strategies That Help (Protein, Fiber, Sleep, Stress) Simple, practical tips can help you regain control
Graphical Abstract Similar content being viewed by others Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 inhibitors (SGLT2) are key treatments for type 2 diabetes that improve cardiovascular and renal outcomes [1,2,3]
%20(1).png)
